Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial

Citation
Cannon CP, Perkovic V, Agarwal R, et al. Circulation 2019;140(Suppl 1): A14752